Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257944 | 1.00 | HSP90AA1 (0.33) | HSP90AA1MEN1LMNAHSP90AB1MAPT | |
| SCHEMBL23037268 | 0.80 | HSP90AA1 (0.33) | HSP90AA1MEN1LMNAHSP90AB1MAPT | |
| SCHEMBL23037266 | 0.80 | HSP90AA1 (0.33) | HSP90AA1MEN1LMNAHSP90AB1MAPT | |
| SCHEMBL11167161 | 0.76 | ALDH1A1 (0.37) | HSP90AA1HSP90AB1MAPTHTT | |
| SCHEMBL10746552 | 0.75 | — | — | |
| SCHEMBL6159661 | 0.75 | — | — | |
| SCHEMBL1247038 | 0.75 | — | — | |
| SCHEMBL8703080 | 0.73 | ALDH1A1 (0.38) | — | |
| SCHEMBL248607 | 0.73 | HRH1 (0.50) | LMNAMAPT | |
| SCHEMBL7176290 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888001-B2 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | LEE JUNG S (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1107965-B1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | ORTHO MCNEIL PHARM INC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030207858-A1 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | LEE JUNG S (US) | 2003-11-06 | — | — | US | disclosed |
| US-6562847-B1 | Useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1107965-A1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010997-A1 | PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207858-A1 | Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. | CHRM1, CHRM5, CHRM2 | HSP90AA1 4080/4885MEN1 3585/4885LMNA 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.